Nature Communications (Jun 2022)
Rapid, adaptable and sensitive Cas13-based COVID-19 diagnostics using ADESSO
- Beatrice Casati,
- Joseph Peter Verdi,
- Alexander Hempelmann,
- Maximilian Kittel,
- Andrea Gutierrez Klaebisch,
- Bianca Meister,
- Sybille Welker,
- Sonal Asthana,
- Salvatore Di Giorgio,
- Pavle Boskovic,
- Ka Hou Man,
- Meike Schopp,
- Paul Adrian Ginno,
- Bernhard Radlwimmer,
- Charles Erec Stebbins,
- Thomas Miethke,
- Fotini Nina Papavasiliou,
- Riccardo Pecori
Affiliations
- Beatrice Casati
- Division of Immune Diversity, Department of Immunology and Cancer, German Cancer Research Centre (DKFZ)
- Joseph Peter Verdi
- Division of Immune Diversity, Department of Immunology and Cancer, German Cancer Research Centre (DKFZ)
- Alexander Hempelmann
- Division of Structural Biology of Infection and Immunity, Department of Immunology and Cancer, German Cancer Research Centre (DKFZ)
- Maximilian Kittel
- Institute of Clinical Chemistry, Medical Faculty of Mannheim, University of Heidelberg
- Andrea Gutierrez Klaebisch
- Mannheim Institute for Innate Immunoscience (MI3), Medical Faculty of Mannheim, University of Heidelberg
- Bianca Meister
- Mannheim Institute for Innate Immunoscience (MI3), Medical Faculty of Mannheim, University of Heidelberg
- Sybille Welker
- Mannheim Institute for Innate Immunoscience (MI3), Medical Faculty of Mannheim, University of Heidelberg
- Sonal Asthana
- Division of Immune Diversity, Department of Immunology and Cancer, German Cancer Research Centre (DKFZ)
- Salvatore Di Giorgio
- Division of Immune Diversity, Department of Immunology and Cancer, German Cancer Research Centre (DKFZ)
- Pavle Boskovic
- Division of Molecular Genetics, German Cancer Research Centre (DKFZ)
- Ka Hou Man
- Division of Molecular Genetics, German Cancer Research Centre (DKFZ)
- Meike Schopp
- Division of Regulatory Genomics and Cancer Evolution, German Cancer Research Centre (DKFZ)
- Paul Adrian Ginno
- Division of Regulatory Genomics and Cancer Evolution, German Cancer Research Centre (DKFZ)
- Bernhard Radlwimmer
- Division of Molecular Genetics, German Cancer Research Centre (DKFZ)
- Charles Erec Stebbins
- Division of Structural Biology of Infection and Immunity, Department of Immunology and Cancer, German Cancer Research Centre (DKFZ)
- Thomas Miethke
- Mannheim Institute for Innate Immunoscience (MI3), Medical Faculty of Mannheim, University of Heidelberg
- Fotini Nina Papavasiliou
- Division of Immune Diversity, Department of Immunology and Cancer, German Cancer Research Centre (DKFZ)
- Riccardo Pecori
- Division of Immune Diversity, Department of Immunology and Cancer, German Cancer Research Centre (DKFZ)
- DOI
- https://doi.org/10.1038/s41467-022-30862-y
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 11
Abstract
SARS-CoV-2 antigen tests are commonly used point-of-care tests and provide rapid results but lack sensitivity. Here, the authors present a new point-of-care approach for COVID-19 diagnosis, “ADESSO”, which outperforms antigen tests on clinical samples and can be quickly adapted for different variants.
